Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
Date:11/3/2009

luted 34,769 34,688 34,723 34,685 ====== ====== ====== ====== Condensed Consolidated Balance Sheets (In thousands) September 30, December 31, 2009 2008 -------------- ------------- (Unaudited) (Note 1) ASSETS: Cash and investment securities $40,114 $72,755 Cash - restricted 281 281 Facilities and equipment, net 277 1,123 Licensed products, net 7,896 8,807 Other assets 1,072 1,266 ----- ----- Total assets $49,640 $84,232 ======= ======= LIABILITIES AND SHAREHOLDERS' EQUITY: Current liabilities $17,574 $19,178 Long term liabilities 11,848 17,407 Shareholders' equity 20,218 47,647 ------ ------ Total liabilities and shareholders' equity $49,640 $84,232 ======= ======= Note 1: Derived from audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2008.

SOURCE Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference
2. Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
3. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
4. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
6. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
7. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
8. Poniard Pharmaceuticals Files Shelf Registration
9. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
10. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
11. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ATTLE,Nov.24/PRNewswire-FirstCall/--CellTherapeuti...ntatthe21stAnnualPiperJaffrayHealthCareConference....rkPalaceHotel. ,, CTIwillpresentonTuesday,Decem...eaudiowebcastofCTI,spresentationwillbeavailableat ...forreplayafterwards. , ,PiperJaffrayHealthCareCon...
(Date:11/23/2009)...N, Ill. You can think of it as origami very high... Illinois have developed a technique for fabricati...tructures from thin films by coupling photolithogr...y interactions. , The films, only a few microns t...sible with thicker pieces of the same material. ,...
(Date:11/23/2009)... consists of a two-dimensional carbon layer in whi...ttice, resembling a honeycomb. Carbon nanotubes ar... graphene sheets form graphite. Graphene boasts so...ear-resistant, an excellent thermal conductor, and...ess and ductility. In addition, graphene is imperm...
(Date:11/23/2009)...SSISSAUGA,ON,Nov.23/PRNewswire-FirstCall/-YMBioSci...uctdevelopmentcompanythatidentifiesandadvancesadiv...riousstagesofdevelopment,todayreportedthatCytopia(...luatingCYT387,apotent,orally-administeredJAK1/JAK2...chester,Minnesota.AproposaltomergeCytopiaintoYMhas...
Breaking Biology Technology:Water droplets direct self-assembly process in thin-film materials 2Polymer with honeycomb structure 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4
...-dose cohorts plus data from subsequent higher-dos..., Calif., March 18 InterMune, Inc. (Nasdaq: ITM...ical study of ITMN-191 (R7227) in combination with...ferred to as the INFORM-1 study, has been accepted... at the 44th Annual Meeting of the European Associ...
.... Wright, Co-Chair of the Alliance for Biosecurity...ied today before the House Labor, Health and Human...ee on the critical importance of developing drugs,... to protect Americans from bioterrorism and other ... countermeasures for many of the chemical, biologi...
...Marin Pharmaceutical Inc. (Nasdaq: BMRN ) announ...authorization (CTA) for BMN 110 or N-acetylgalacto...ment of the lysosomal storage disorder Mucopolysac...me, has been accepted by the United Kingdom Medici...A). BioMarin expects to initiate a Phase 1/2 clini...
Other Biology Technology:INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 2INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 3INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 4Alliance for Biosecurity Testifies Before Congress on Funding for Medical Countermeasure Development 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4
(Date:11/24/2009)...that may help gut bacteria bind to the gastrointes...c producers to identify strains that are likely to... to interact with cells lining the gut to have a b...n the gut they are more likely to stick around lon...e Juge from the Institute of Food Research. IFR i...
(Date:11/24/2009)...dical Toxicology (ACMT) have signed an agreement t...f Medical Toxicology (JMT), the official journal ...iously published by the University of Pennsylvania...an international, peer-reviewed journal, is dedica...al toxicology. The quarterly journal focuses on t...
(Date:11/24/2009)... of debate. A high-profile study a few years ago s...carbon from trees and leaves, evidence for a very ...systems. , But new research from the University ... Algae provide a much richer diet for fish and oth...his week in the Proceedings of the National Acade...
Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2Springer and the American College of Medical Toxicology to work together 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Minorities Less Likely to Have Blood Pressure Under Control 58190 1Minorities Less Likely to Have Blood Pressure Under Control 58190 2Minorities Less Likely to Have Blood Pressure Under Control 58190 3The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 58185 1The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 58185 2The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 58185 3Aviva Family and Childrens Services Hosts Rededication Ceremony of the Newly Renovated Wallis Annenberg Center 58180 1Aviva Family and Childrens Services Hosts Rededication Ceremony of the Newly Renovated Wallis Annenberg Center 58180 2
...ilian personnel from the U.S. Armed Forces, as wel...aw enforcement and other first-responder personnel...dia have been encouraged to register and attend th...PED VII). The event will be held at Stafford Regio...uring May 19-21. , , The demonstration, which is ...
..., University of Alabama at Birmingham professor of...Prize for Outstanding Innovation in Life Sciences....salutes Weaver,s achievements in advancing underst...ough T cell research. , According to Weaver, our...and cancer, but when T cells overreact and turn on...
...ng diverse forests for multiple uses is important ...dy conducted in southwestern Oregon provides fores...en managing land for a variety objectives that may...te level of wood production with some wildlife hab...s cover and forage for a wider variety of wildlife...
Other Biology News:Demonstration Features Commercial Technology for Combating Terrorism 2UAB professor receives HudsonAlpha Innovation Prize 2Managing Douglas-fir forests for diversity 2
PARP Cleavage Immunoblotting Assay Kit from Upstate
...o-Sequencing is designed to aid sequence analysis ...ning sites (MCS) of M13 phage vectors (mp18/19) or...). The kit is used to create nested unidirectional...y moving the primer binding site on the vector clo...
MaxArray Rat Brain Tissue Slides from Invitrogen
...ion Kit, 100 reactions. Prepare circular DNA templ...ram quantities of template DNA from picogram amoun... for cycle sequencing without purification.Amplify...es, plaques, or purified circular (plasmid or M13)...
Biology Products: